Sophiris Bio Inc. Reports Fourth Quarter And Full Year 2013 Financial Results And Key Operational Highlights
Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced financial results and recent key operational highlights for the three months and full year ended December 31, 2013.
Help employers find you! Check out all the jobs and post your resume.